Immunovant, Inc. (IMVT)
Sous-évaluéFondamental
23
Prix
$33.78
Capitalisation boursière
$6.98B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users
argenx sells efgartigimod (Vyvgart), the first approved FcRn blocker, and competes with Immunovant's IMVT-1402 for the same autoimmune patients in myasthenia gravis, CIDP and other IgG-driven diseases.
Johnson & Johnson markets the FcRn blocker nipocalimab (Imaavy) in generalized myasthenia gravis and is expanding it into Sjögren's disease and other indications Immunovant is also targeting.
UCB's rozanolixizumab (Rystiggo) is an approved FcRn blocker for generalized myasthenia gravis, competing for the same neurologists and the same patients Immunovant's lead programme addresses.
Viridian sells veligrotug (Lumvoa) for thyroid eye disease and is developing its own FcRn inhibitors, putting it head-to-head with Immunovant in the thyroid autoimmune indications built around Graves' disease.
Biohaven is developing BHV-1300, an IgG-degrading therapy aimed at Graves' disease and other antibody-driven autoimmune conditions, the same indications Immunovant has chosen for IMVT-1402.
Bilan & Liquidités
Chiffre d'affaires
0
Exercice clos le 31/03/2026
Résultat net
$-506M
Exercice clos le 31/03/2026
Flux de trésorerie libre
$-407M
Capitaux propres totaux
$853M
Passif total
$104M
Ratio de liquidité général
7.27
Couverture des intérêts
-
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
Aucune donnée de résultat disponible
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$48.88
Prix actuel
$33.78
Marge de sécurité
+30.9%
Fourchette de juste valeur
$46.43 - $51.32
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-59.3%
Ratio P/B
9.49
P/FCF
-
Marge brute
-
ROIC
-
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
-
WACC
9.6%
ROIC − WACC
-
Critères d'analyse fondamentale
Réussi (5)
- Price CAGR 11.75%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 78% Buy
Échoué (9)
- EPS shows upward trend
- P/B Ratio 9.49
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -69.6%
- Earnings Surprise avg -5.5%
- Share Dilution 20.4%
- Piotroski F-Score 2/9
Indisponible (13)
- ROIC NaN%
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 46 |
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director | 38 |
| Mr. Tiago M. Girao CPA | Chief Financial Officer | 46 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 47 |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer | 62 |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | 50 |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | - |
| Ms. Becky Merlina | Senior VP & Global Head of Quality | - |
| Ms. Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management | - |
| Ms. Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development | - |
Risque d'audit
4
Risque du conseil
10
Risque de rémunération
9
Risque droits des actionnaires
10
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-05-20
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-06
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-09-03
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for IMVT, sourced from Markets Gazette.
- 3/15/2026POSITIVEA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
A healthcare hedge fund has significantly increased its stake in Immunovant Inc., acquiring an additional $24.5 million worth of stock. Immunovant is a clinical-stage biopharmaceutical company focused on developing antibody therapies for autoimmune diseases. Its lead candidate is currently undergoing Phase II trials. This substantial investment by a specialized healthcare fund suggests strong conviction in the company's pipeline and future prospects. For investors, this move could signal positive upcoming developments or a favorable risk-reward profile for Immunovant's stock.
- 3/11/2026POSITIVEImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Inc. (IMVT) experienced a significant surge, with its stock price climbing 30%. This upward momentum comes despite a notable insider trimming their stake by $3 million. The company, which focuses on antibody therapies for autoimmune diseases, has seen its lead candidate advance through clinical trials. This progress in its drug development pipeline is a key driver for investor optimism, suggesting potential future revenue streams and market expansion. The stock's performance indicates strong market confidence in Immunovant's therapeutic pipeline and its long-term growth prospects, outweighing the impact of the insider's partial divestment.
via Markets Gazette